This Year's Highlights

• Successful Pre-IND meeting.
• Initial safety demonstrated in primates.
• Pipeline demonstrated via PNT 200 for breast cancer; DNAi? HiT platform established.

Anticipated Highlights

• Bridge financing underway, rolling closes October 23, 2006.
• Initiate IND enabling preclinical studies.
• Commence B-Round financing.

Corporate Mission

ProNAi seeks to offer novel and effective treatments for complex human diseases focusing initially on oncology and the development and validation of its proprietary nucleic acid-based therapeutic drug technology, DNAi?, providing challenging and rewarding careers for employees and creating value to shareholders. ProNAi's platform technology has supported the expansion of a portfolio of promising DNAi? drug candidates which the company is currently developing and validating in animal models. As a result of the Company's recent pre-IND FDA meeting, ProNAi intends to file its first INDs for indolent Non-Hodgkins Lymphoma in early 2007, based on its lead candidate.

ProNAi is currently located in Kalamazoo, Michigan, occupying 2,000 square feet of fully outfitted and instrumented laboratory space within the Southwest Michigan Innovation Center (a biotechnology accelerator). Company operations are supported by 10 full-time staff, complemented by experienced pharmaceutical industry consultants.